Search Results | Blood | American Society of Hematology

1-20 of 84

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis

Joseph G Schroers-Martin, Joanne Soo, Gabriel Brisou, Florian Scherer, David M. Kurtz, Brian Sworder, Michael S. Khodadoust, Michael C. Jin, Agnès Bru, Chih Long Liu, Henning Stehr, Paolo Vineis, Yasodha Natkunam, Lauren R Teras, Joo Y. Song, Bertrand Nadel, Maximilian Diehn, Sandrine Roulland, Ash A. Alizadeh

Blood (2021) 138 (Supplement 1): 709.

DOI: https://doi.org/10.1182/blood-2021-151058

Published: 2021

Journal Articles

Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma

Blood (2021) 138 (Supplement 1): 3519.

DOI: https://doi.org/10.1182/blood-2021-152801

Published: 2021

Journal Articles

S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements

Elizabeth A Brem, Hongli Li, Anne W. Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh, Rebecca L. Olin, Norah Lynn Henry, Hildy Dilon, Richard F. Little, Cara Laubach, Michael L. Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 3565.

DOI: https://doi.org/10.1182/blood-2021-148193

Published: 2021

Journal Articles

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

Blood (2021) 138 (Supplement 1): 524.

DOI: https://doi.org/10.1182/blood-2021-145228

Published: 2021

Journal Articles

Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma

Tanaya Shree, Vishnu Shankar, Debra K. Czerwinski, Gladys Rodriguez, Sara Beygi, Joseph G Schroers-Martin, Ranjana Advani, Lauren S. Maeda, Neel K. Gupta, Michael S. Khodadoust, David M. Kurtz, Karen S. Corbelli, Etelka Gabriel, Alyssa M. Kanegai, Ash A. Alizadeh, Ronald Levy

Blood (2021) 138 (Supplement 1): 2064.

DOI: https://doi.org/10.1182/blood-2021-153901

Published: 2021

Journal Articles

Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma

Blood (2021) 138 (Supplement 1): 233.

DOI: https://doi.org/10.1182/blood-2021-144610

Published: 2021

Journal Articles

Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma

Blood (2021) 138 (Supplement 1): 6.

DOI: https://doi.org/10.1182/blood-2021-149644

Published: 2021

Journal Articles

Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing

Mohammad Shahrokh Esfahani, Stefan Alig, Mahya Mehrmohamadi, Emily G. Hamilton, Daniel A King, Andre Schultz, Chloe B. Steen, Charles Macaulay, Brian Sworder, David M. Kurtz, Maximilian Diehn, Ash A. Alizadeh

Blood (2021) 138 (Supplement 1): 37.

DOI: https://doi.org/10.1182/blood-2021-150964

Published: 2021

Journal Articles

Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma

Ivana Spasevska, Sarah Josefsson, PhD MSc, Yngvild Nuvin Blaker, MD PhD, Chloe B. Steen, PhD, Ankush Sharma, PhD, Kushi Kushekhar, PhD MSc, Saskia Meyer, PhD, Arne Kolstad, MD PhD, Klaus Beiske, MD PhD, Harald Holte, MD PhD, Bjørn Østenstad, MD PhD, Eva Kimby, MD PhD, Johanna Olweus, PhD, Kjetil Tasken, PhD, Suzanne Lorenz, PhD, Erlend B. Smeland, PhD MD, Ash A. Alizadeh, MD PhD, Kanutte Huse, PhD, June Helen Myklebust, PhD

Blood (2020) 136 (Supplement 1): 27–28.

DOI: https://doi.org/10.1182/blood-2020-142380

Published: 2020

Journal Articles

Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage

Joseph G Schroers-Martin, MD, Joanne Soo, MD, Gabriel Brisou, MD, Florian Scherer, MD, David M. Kurtz, MDPhD, Brian Sworder, MD PhD, Michael S. Khodadoust, MD PhD, Michael C. Jin, BS, Agnès Bru, Chih Long Liu, PhD, Henning Stehr, PhD, Paolo Vineis, PhD, Yasodha Natkunam, MD PhD, Bertrand Nadel, PhD, Maximilian Diehn, MD PhD, Sandrine Roulland, PhD, Ash A. Alizadeh, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

DOI: https://doi.org/10.1182/blood-2020-142761

Published: 2020

Journal Articles

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

Navika D Shukla, Alexander F. M. Craig, MPhil, Brian Sworder, MD PhD, David M. Kurtz, MDPhD, Charles Macaulay, MSc, BA, Andrea Garofalo, BS, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, George Duran, BA, Youn H. Kim, MD, James Zehnder, MD, Crystal L. Mackall, MD, David B. Miklos, MD PhD, Maximilian Diehn, MD PhD, Michael S. Khodadoust, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2020) 136 (Supplement 1): 49–50.

DOI: https://doi.org/10.1182/blood-2020-141655

Published: 2020

Journal Articles

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Blood (2020) 136 (Supplement 1): 53–54.

DOI: https://doi.org/10.1182/blood-2020-139605

Published: 2020

Journal Articles

Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma

Irl Brian Greenwell, MD, Jeffrey M. Switchenko, PhD MS, Kami J. Maddocks, MD, Brad S. Kahl, MD, Alexander F. M. Craig, MPhil, Ash A. Alizadeh, MD PhD, Pamela B. Allen, MD MSc, Alena Lorretta Marbury, BS, Alicia Escobar, Kelly Valla, PharmD, Miayea Williams, Priya Parikh, Danielle Roberts, PA-C, Jessica J. Neely, PA-C, Alexandra Palmer, NP-C, Kristie A. Blum, MD, Jonathon B. Cohen, MDMS

Blood (2020) 136 (Supplement 1): 33–34.

DOI: https://doi.org/10.1182/blood-2020-141454

Published: 2020

Journal Articles

Newest Discoveries Using Next Generation Sequencing Approaches for Minimal Residual Disease

Ash A. Alizadeh, MD PhD

Blood (2020) 136 (Supplement 1): SCI2.

DOI: https://doi.org/10.1182/blood-2020-133040

Published: 2020

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

DOI: https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

Chloe B. Steen, MSc, Bogdan A. Luca, PhD, Mohammad Shahrokh Esfahani, Barzin Y. Nabet, PhD, Brian Sworder, MD PhD, Farshad Farshidfar, MD PhD, Kiarash Shamardani, BA, David M. Kurtz, MD PhD, Chih Long Liu, PhD, Ranjana H Advani, MD, Yasodha Natkunam, MD PhD, June Helen Myklebust, PhD, Maximilian Diehn, MD PhD, Andrew Gentles, PhD, Aaron M Newman, PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 655.

DOI: https://doi.org/10.1182/blood-2019-129461

Published: 2019

Journal Articles

Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment

Lisa E Wagar, PhD, Brian Sworder, MD PhD, Michael S. Khodadoust, MD PhD, Mark M Davis, PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 2799.

DOI: https://doi.org/10.1182/blood-2019-131192

Published: 2019

Journal Articles

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Stefan Alig, MD, Charles Macaulay, MSc, BA, David M. Kurtz, MD PhD, Ulrich Dührsen, Prof, MD PhD, Andreas Hüttmann, MD, Michael C. Jin, BS, Brian Sworder, MD PhD, Andrea Garofalo, BS, BA, Mohammad Shahrokh Esfahani, Joanne Soo, MD, Florian Scherer, MD, Alexander Craig, MPhil, Olivier Casasnovas, MD, Jason R. Westin, MD, Gianluca Gaidano, MD PhD, Davide Rossi, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 491.

DOI: https://doi.org/10.1182/blood-2019-129283

Published: 2019

Journal Articles

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Brian Sworder, MD PhD, David M. Kurtz, MD PhD, Charles Macaulay, MSc, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, Andrea Garofalo, BS, BA, Bita Sahaf, PhD, Mohammad Shahrokh Esfahani, Jay Y. Spiegel, MDFRCPC, Jean Oak, MD PhD, Sara Beygi, MD, Michael C. Jin, BS, Jacob J Chabon, Michael S. Khodadoust, MD PhD, Robbie G. Majzner, MD, Crystal L. Mackall, MD, Maximilian Diehn, MD PhD, David B Miklos, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 550.

DOI: https://doi.org/10.1182/blood-2019-129015

Published: 2019

Journal Articles

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling

Mohammad Shahrokh Esfahani, Stefan Alig, MD, David M. Kurtz, MD PhD, Joanne Soo, MD, Michael C. Jin, BS, Charles Macaulay, MSc, BA, Alexander F. M. Craig, MPhil, Andrea Garofalo, BS, BA, Chloe B. Steen, MSc, Florian Scherer, MD, Brian Sworder, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 551.

DOI: https://doi.org/10.1182/blood-2019-132069

Published: 2019

2 3 4 5

NARROW

Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis

Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma

Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma

Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma

Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing

Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma

Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma

Newest Discoveries Using Next Generation Sequencing Approaches for Minimal Residual Disease

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only